Search Results

Owens & Minor, Inc. reported financial results for the first quarter ended March 31, 2024.

Owen Mumford, a global leader in the design, manufacture and advancement of medical devices announced that it has appointed Bal Johal as Director of Research and Development, effective from 4th July 2022.

Owens & Minor, Inc. plans to release financial results for the first quarter of 2024 on Friday, May 3, 2024, before trading begins on the New York Stock Exchange.

Monte Rosa Therapeutics, Inc. announced that Owen Wallace, Ph.D., the Company’s Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK-based biotechnology company.

Owens & Minor, Inc. announced that Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer and Jonathan Leon, the Company’s Senior Vice President-Finance and Corporate Treasurer, will be participating in a webcasted fireside chat at 5:20 p.m. Eastern Daylight Time on Wednesday, May 15, 2024 at BofA Securities’ 2024 Health Care Conference in Las Vegas, Nevada.

Owens & Minor, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus® auto-injector.

C4 Therapeutics, Inc. today announced the appointment of Owen Hughes to its board of directors.